NCT02805023 - BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

December 31, 2027

Conditions

Chronic Limb-Threatening IschemiaPeripheral Arterial DiseasePeripheral Vascular Disease

Interventions

BIOLOGICAL

BGC101 (autologous EnEPC preparation)

Intramuscular injections - single treatment session

BIOLOGICAL

Control medium

Intramuscular injections - single treatment session

Trial Locations (5)

Johns Hopkins Hospital, Baltimore

Rambam Health Care Campus, Haifa

Laniado Hospital, Netanya

University of San Francisco, San Francisco

Yale University School of Medicine, New Haven